Log in to your Inderes Free account to see all free content on this page.

LIDDS

0.05 SEK

-12.94 %

Less than 1K followers

LIDDS

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-12.94 %

-16.16 %

-17.55 %

+24.50 %

-50.94 %

-54.73 %

-98.35 %

-99.62 %

-99.48 %

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

Market cap

6.8M SEK

Turnover

2.95K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18.12.

2025

Extraordinary general meeting '25

19.2.

2026

Annual report '25

28.5.

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Regulatory press release12/1/2025, 4:15 PM

Change of Certified Adviser (CA) to G&W Fondkommission

Regulatory press release11/27/2025, 5:30 PM

LIDDS AB (publ) has entered into an agreement for a reverse takeover of Proport Invest AB (publ)

Regulatory press release11/20/2025, 6:00 AM

LIDDS AB (publ) Interim Report January – September 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/13/2025, 8:20 PM

Notice of extraordinary general meeting in LIDDS AB (publ)

Press release11/13/2025, 8:10 PM

The board of directors of LIDDS AB intends to propose a reduction of the company’s share capital for loss coverage

Regulatory press release8/28/2025, 6:00 AM

LIDDS AB (publ) Interim Report January – June 2025

Regulatory press release5/28/2025, 9:00 AM

Announcement from Annual General Meeting, also first control meeting, in LIDDS AB (publ), held on 28 May 2025

Regulatory press release5/28/2025, 6:32 AM

Correction: LIDDS AB (publ) Interim Report January – March 2025

Regulatory press release5/28/2025, 6:00 AM

LIDDS AB (publ) Interim Report January – March 2024

Regulatory press release5/6/2025, 6:00 AM

LIDDS’ Annual Report 2024 published

Regulatory press release4/25/2025, 8:15 AM

Notice to the Annual General Meeting, and first Control Meeting, of LIDDS AB (publ)

Regulatory press release4/24/2025, 8:45 PM

Balance Sheet shows that the Equity in LIDDS AB is Less than Half of the Registered Share Capital and the Board will therefore convene a First Control Meeting

Regulatory press release4/22/2025, 6:10 AM

The Board of Directors resolves to prepare a balance sheet for liquidation purposes

Regulatory press release4/10/2025, 11:30 AM

LIDDS has decided to write-down intangible assets

Regulatory press release4/2/2025, 1:00 PM

LIDDS has decided to cease further development

Regulatory press release2/20/2025, 7:00 AM

LIDDS AB (publ) Year-end Report 2024

Press release12/3/2024, 9:00 AM

Nomination Committee appointed for the Annual General Meeting 2025 in LIDDS

Regulatory press release11/21/2024, 7:00 AM

LIDDS AB (publ) Interim Report January – September 2024

Press release9/26/2024, 3:00 PM

LIDDS has decided to concentrate its activities on three project areas

Regulatory press release8/28/2024, 8:00 AM

LIDDS AB (publ) Interim Report January – June 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.